-+ 0.00%
-+ 0.00%
-+ 0.00%
According to the Zhitong Finance App, Goli Pharmaceutical-B (01672.HK) issued an announcement. Goli has submitted a new drug clinical trial application (IND) for ASC36_37o FDC to the US Food and Drug Administration (FDA) to treat obesity. ASC36_37O FDC is a weekly oral fixed-dose combination (FDC) tablet of the insulin agonist polypeptide ASC36 and GLP-1R/GIPR/GCGR tri-target agonist polypeptide ASC37.
Share
Listen to the news
According to the Zhitong Finance App, Goli Pharmaceutical-B (01672.HK) issued an announcement. Goli has submitted a new drug clinical trial application (IND) for ASC36_37o FDC to the US Food and Drug Administration (FDA) to treat obesity. ASC36_37O FDC is a weekly oral fixed-dose combination (FDC) tablet of the insulin agonist polypeptide ASC36 and GLP-1R/GIPR/GCGR tri-target agonist polypeptide ASC37.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending